TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01855893

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auto-acupressure
Description: Patients will receive instructions about how to apply auto-acupressure once in a day during one week by their health care professionals.This technique will be complementary to the conventional treatment.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional treatment
Description: Conventional treatment consist of: 7 days with paracetamol 1g /8 hours and/ or ibuprofen 400mg/ 8 hours, and tetrazepam 50 mg/ 12 hours
Study: NCT03944850

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Anxiety Sensitivity Treatment
Description: CAST is a newly developed computerized intervention designed to closely model the educational and behavioral techniques that are commonly used in the treatment of anxiety and related conditions. A psychoeducation component focuses on the nature of anxiety and its effects on the mind and body. Veterans will be taught that physiological and psychological arousal is not dangerous, although they may have developed a conditioned fear of this arousal. Interoceptive exposure (IE) exercises will also be introduced to as a way to reduce or eliminate the conditioned fear response.
Study: NCT01265485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: coated suppository
Description: Dose escalating study
Study: NCT03101800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine and Allopurinol
Description: Low dose Azathioprine in combination with allopurinol 100 mg for 1 year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: Standard weight based azathioprine dosage
Study: NCT02542618

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inquiry Based Stress Reduction (IBSR)
Study: NCT03416686

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF star electrode electrode_Fixed)
Description: The radiofrequency will be performed under ultrasound control after local anesthesia by a trained operator, after finding the lesion to be treated by the operator.~Medical device used: RF star electrode electrode_Fixed (Starmed Co,Gyeonggi-do, Korea, French representative Cosysmed).
Study: NCT01018719

Intervention type: DEVICE
Intervention: MDCT, ECG, Echocardiography
Description: Multi-detector computed tomography to evaluate coronary artery patency; ECG and Echocardiography - to evaluate cardiac function.

Intervention type: DEVICE
Intervention: MDCT, ECG, Echocardiography
Description: Multi-detector computed tomography to evaluate coronary artery patency; ECG and Echocardiography - to evaluate cardiac function.
Study: NCT03191669

Intervention type: OTHER
Intervention: Auto-questionnaire
Description: Single Auto-questionnaire administered during or after a consultation/hospitalization
Study: NCT02542618

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Study: NCT05003193

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pedometer
Description: 2000 steps per day in 20 minutes for 90 days, guided by a pedometer after a kidney transplantation
Study: NCT04219410

Intervention type: PROCEDURE
Intervention: Fully minimally invasive esophagectomy
Description: Esophagectomy using a novel fully minimally invasive approach
Study: NCT03249363

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group A - Pulsed PVP-I Irrigation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group A - Pulsed PVP-I Irrigation
Study: NCT01675024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine, Period 2
Description: Formulation: transdermal~Dosage: 2 mg / 24 hours for 3 days from Day 7 to Day 9, 4 mg / 24 hours for 3 days from Day 10 to Day 12~Frequency: once every 24 hours~Duration: from Day 1 to Day 3
Study: NCT03978182

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: accelerated deep rTMS
Description: A Magstim Rapid2 Plus1 Magnetic Stimulator connected to the Brainsway dTMS system with the H1-coil investigational device (Brainsway Ltd, Jerusalem, Israel). The coil is situated inside a helmet to achieve effective cooling during stimulation. A sham coil is also included in the same helmet. The sham coil mimics scalp sensations and the acoustic artifact of the active stimulation without inducing neuronal activation.
Study: NCT02554734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa, carbidopa, ODM-104
Study: NCT03978182

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: accelerated deep rTMS
Description: A Magstim Rapid2 Plus1 Magnetic Stimulator connected to the Brainsway dTMS system with the H1-coil investigational device (Brainsway Ltd, Jerusalem, Israel). The coil is situated inside a helmet to achieve effective cooling during stimulation. A sham coil is also included in the same helmet. The sham coil mimics scalp sensations and the acoustic artifact of the active stimulation without inducing neuronal activation.
Study: NCT01258530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: over-encapsulated oseltamivir
Description: 75 mg once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oseltamivir
Description: 75 mg once
Study: NCT04566822

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Touch intervention
Description: The Calm app is downloadable by participants onto their smartphone to access the Calm app and Calm Sleep Coaching. The Calm app is used to deliver the intervention to experimental group participants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medium Touch intervention
Description: The Calm app is downloadable by participants onto their smartphone to access the Calm app and Calm Sleep Coaching. The Calm app is used to deliver the intervention to experimental group participants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Touch intervention
Description: The Calm app is downloadable by participants onto their smartphone to access the Calm app and Calm Sleep Coaching. The Calm app is used to deliver the intervention to experimental group participants.
Study: NCT01029535

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cross-linked hyaluronic acid gel
Description: Cross-linked hyaluronic acid gel (Juvederm® VOLUMA™) up to 4 mLs injected in each side of the face.
Study: NCT01891929

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RECOS (COgnitive REmediation for Schizophrenia)
Description: Every RECOS patient will benefit, with his therapist, from 2 sessions of 1 hour of training per week over a 14 weeks period (M1 to M3), plus 1 hour per week of task to be realized at home. All in all, it is thus about a training period of 42 hours.~After remediation, the follow-up of the patient will be led by his therapist with monthly appointments during 6 months (M4 to M9).~In parallel, neuropsychological and clinical scores will be assessed before (M0) and after the training period (M3), as well as at the end of the study (M9). Working and relational abilities will be assessed at the beginning and at the end of the working period (M4 and M9).
Study: NCT04566822

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sleep Education Control
Description: Participants in the sleep education control will not have access to a coach. Weekly sleep education will be accessible to the participant on a weekly basis. The sleep education content will be the same that is provided to the intervention participants.
Study: NCT01895491

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VM206DNA

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VM206DNA

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VM206DNA
Study: NCT01891929

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU (Treatment As Usual)
Description: The treatment of the group TAU (Treatment As Usual) will consist of the usual care proposed by every service of the various inquiring centers involved. No additional session will be proposed.~In parallel, neuropsychological and clinical scores will be assessed before (M0) and after the training period (M3), as well as at the end of the study (M9). Working and relational abilities will be assessed at the beginning and at the end of the working period (M4 and M9).
Study: NCT01895491

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VM206Ad

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VM206Ad

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VM206Ad
Study: NCT02554734

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levodopa, carbidopa, entacapone
Study: NCT01079832

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiosurgery
Description: Radiation will be delivered in 3 fractions. The dose level will range between 500 to 800cGy per fraction at the discretion of the treating radiation oncologist

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT04587102

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: whole body viberation
Description: vibration training in the form of whole body vibration for 20-30 minutes per session, 3 sessions per week for 8 weeks. The vibration training was performed on a whole body vibration platform

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional program(balance exercises and resisted exercises)
Description: balance exercises and resisted exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional program(balance exercises and resisted exercises)
Description: balance exercises and resisted exercises
Study: NCT00926016

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone (Actos)
Description: pioglitazone 45 mg a day
Study: NCT03593213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Cariprazine capsules, oral administration, once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules, oral administration, once daily.
Study: NCT04194749

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Media Based Physical Therapy
Description: This intervention is a modified post immobilization protocol. This will include giving the patients a USB drive loaded with a 12 week therapy protocol presented in digital form with videos and graphical representations of exercises to be done. They will also have access to the videos and multimedia on the Oregon Health \& Science University website.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Physical Therapy
Description: This intervention is a 12 week therapist supervised clinic-based therapy protocol.
Study: NCT00309907

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: etanercept
Description: Given IV and subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: Given IV and orally
Study: NCT01190007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caduet
Description: One Caduet tablet will be administered once daily after breakfast, in principle, for 52 weeks
Study: NCT00609310

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flavonoids
Description: Nutritional Supplement: flavonoid mixture with 20 mg apigenin and 20 mg epigallocathechin gallate as tablets per day
Study: NCT03966508

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High-frequency electrical stimulation
Description: High-frequency stimulation will be applied on the volar forearm (6-10 cm distal to the cubital fossa). To avoid any confounding effect of handedness, the arm onto which HFS will be applied twice (dominant vs nondominant) will be counterbalanced across participants. HFS will consist of 12 trains of 42 Hz electrical pulses lasting 1 s each. The time interval between each train will be 10 s. The intensity of stimulation will be 5mA. Electrical pulses will be delivered to the skin using a specifically-designed electrode designed: the cathode consists of 16 blunt stainless-steel pins with a diameter of 0.2 mm protruding 1 mm from the base. The 16 pins are placed in a circle with a diameter of 10 mm. The anode consists of a surrounding stainless-steel ring having an inner diameter of 22 mm and an outer diameter of 40 mm. This procedure induces secondary pinprick hyperalgesia (an increase in pinprick sensitivity in a large area of the skin).
Study: NCT00428519

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant
Description: Aprepitant at a dose of 125 mg daily for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant
Description: Aprepitant at a dose of 250 mg daily for 14 days
Study: NCT00559286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Description: application of 80mg or 20mg Telmisartan per day for 30 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan
Description: application of 80mg or 20mg Telmisartan per day for 30 days
Study: NCT00534183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Olanzapine in dose range of 10-20mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Risperidone 1-6mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: Haloperidol 10-20mg
Study: NCT02378337

Intervention type: OTHER
Intervention: Image quantify
Description: Will be observed all patients who perform PET / CT examinations, independent of clinical indication, in nuclear medicine at Hospital Sao Rafael. Those who show interest in participating in the study, will be provided free and informed consent form (ICF) for your appreciation. This evaluation will serve for analysis and quantification of PET-CT images.

Intervention type: OTHER
Intervention: Image quantify
Description: Will be observed all patients who perform PET / CT examinations, independent of clinical indication, in nuclear medicine at Hospital Sao Rafael. Those who show interest in participating in the study, will be provided free and informed consent form (ICF) for your appreciation. This evaluation will serve for analysis and quantification of PET-CT images.
Study: NCT03860532

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HMPL-011 tablets
Description: Eligible subjects will recieve 1200 mg HMPL-011 tablets under fed and diet circumstance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HMPL-011 capsules
Description: Eligible subjects will recieve 1200 mg HMPL-011 capsules under fed and diet circumstance.
Study: NCT01291615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 800mg/m2 - 1000mg/m2, day 1 every 3 weeks. day 1, 15 every 4 weeks. day 1, 8 every 3 weeks. day 1, 8, 15, every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1 40mg/day - 120mg/day (depend on body surface area) day 1-14, every 3 weeks day 1-28, every 6 weeks.
Study: NCT02529995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9291 40 mg
Description: This is a two parts (Part A and Part B) study to determine the pharmacokinetics of AZD9291 administered orally at two dose levels (40 mg Cohort 1 and 80 mg Cohort 2) in patients with locally advanced or metastatic NSCLC who have progressed following prior therapy with an EGFR TKI agent (+/- additional chemotherapy regimens).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9291 80 mg
Description: This is a two parts (Part A and Part B) study to determine the pharmacokinetics of AZD9291 administered orally at two dose levels (40 mg Cohort 1 and 80 mg Cohort 2) in patients with locally advanced or metastatic NSCLC who have progressed following prior therapy with an EGFR TKI agent (+/- additional chemotherapy regimens).
Study: NCT02540746

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ERG Skills Training
Description: Group-based Dialectical Behavior Therapy Skills Training for 12 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ERG Skills Training
Description: Group-based Dialectical Behavior Therapy Skills Training for 12 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ERG Skills Training
Description: Group-based Dialectical Behavior Therapy Skills Training for 12 weeks
Study: NCT03548038

Intervention type: OTHER
Intervention: taste test
Description: All subjects will complete a procedure to determine their taste sensitivity to sweet tastants.
Study: NCT01195974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YASMIN
Description: YASMIN for 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YASMIN
Description: YASMIN for 21 days

Intervention type: DRUG
Group type: OTHER
Intervention: YASMIN
Description: YASMIN for 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2248761
Description: 200 mg GSK2248761 taken on Days 1 - 10 or Days 12 - 21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2248761
Description: 200 mg GSK2248761 taken on Days 1 - 10 or Days 12 - 21

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo taken on Days 1 - 10 or Days 12 - 21

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo taken on Days 1 - 10 or Days 12 - 21
Study: NCT04373304

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low FODMAP diet
Description: A diet specifically developed for the management of IBS is the low Fermentable Oligosaccharides, Disaccharides, Monosaccharides, And Polyols (FODMAP) diet. FODMAP is a collective term that includes fructose in excess of glucose, oligosaccharides including fructans/fructo-oligosaccharides (FOS), galacto-oligosaccharides, sugar polyols such as sorbitol and mannitol, and lactose. Controlled studies have established efficacy of the low FODMAP in managing IBS symptoms, but this diet is complex, associated with low calorie intake, and requires individualized explanation and follow-up by an experienced dietician.
Study: NCT02429258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Farxiga
Description: Farxiga 10mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin background therapy \>/= 1500mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Metformin background therapy \>/= 1500mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin \>/= 30 units

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin
Description: Insulin \>/= 30 units
Study: NCT02723266

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STOPPING-GDM
Description: Educational counseling and skills building Intervention
Study: NCT01828710

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Myo-inositol normospermic
Description: 4000mg/die of myo-inositol and 400 µg of folic acid (Inofolic® Lo.Li. pharma s.r.l., Roma) for three months.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Myo-inositol OAT
Description: B 13 OAT patients treated with 4000mg/die of myo-inositol associated to 400 µg of folic acid (Inofolic® Lo.Li. pharma s.r.l., Roma) for three months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Folic Acid normospermic
Description: Group C 20 normospermic patients treated with 400 µg of folic acid (kindly provided by Lo.Li. pharma s.r.l., Roma) for three months.
Study: NCT00625898

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75 mg/m2 IV on day 1 every 3 weeks for cycles 1-6, Arms 1A and 1B~100 mg/m2 on day 1 every 3 weeks for cycles 1-3, Arms 2A and 2B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2 IV on day 1 every 3 weeks for cycles 1-6, Arms 1A and 1B~100 mg/m2 on day 1 every 3 weeks for cycles 1-3, Arms 2A and 2B

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75 mg/m2 IV on day 1 every 3 weeks for cycles 1-6, Arms 1A and 1B~100 mg/m2 on day 1 every 3 weeks for cycles 1-3, Arms 2A and 2B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2 IV on day 1 every 3 weeks for cycles 1-6, Arms 1A and 1B~100 mg/m2 on day 1 every 3 weeks for cycles 1-3, Arms 2A and 2B
Study: NCT04167176

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: Patients will be placed on their right side. A high-frequency linear ultrasound probe will be placed in a longitudinal parasagittal orientation 2.5-3 cm lateral to the T9 spinous process. The erector spinae muscles will be identified superficial to the tip of the T9 transverse process. A 21G 10-cm needle will be inserted using an in-plane approach in a cranial to caudal direction. The tip of the needle will be placed into the fascial plane on the deep aspect of the erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting the erector spinae muscle off the bony shadow of the transverse process on ultrasonographic imaging. A volume of 20 mL of LA mixture (10 mL of bupivacaine 0.5%, 5 mL of lidocaine 2% and 5 mL of normal saline to make a mixture totaling 20 ml.) will be injected. The same procedure will be repeated for the opposite side.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Port site infiltration
Description: After the induction of anaesthesia, pre-incisional port-site infiltration will be performed by the same surgeon every time with 20 ml of the LA mixture. The volume will be divided equally between port sites. A total of four ports-supraumbilical, subxiphoid and two ports in the right subcostal area at mid-clavicular and anterior axillary line will be made.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound machine (Mindray DP 9900 plus; Mindray Bio-Medical Electronics, Shenzhen, China)
Description: Ultrasound will be used to identify the erector spinae muscles and to guide the LA mixture injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.5%
Description: Bupivacaine 0.5% will be included in the injected LA mixture.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.5%
Description: Bupivacaine 0.5% will be included in the injected LA mixture.
Study: NCT02540746

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ERG Skills Training
Description: Group-based Dialectical Behavior Therapy Skills Training for 12 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement
Description: Three week Motivational Enhancement group
Study: NCT04167176

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 2%
Description: Lidocaine 2% will be included in the injected LA mixture.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 2%
Description: Lidocaine 2% will be included in the injected LA mixture.